April 30, 2024
Genetic Signatures (GSS:ASX) – Leadership Transition at Genetic Signatures
Dr. John Melki has stepped down from his role as CEO of the Company and from the Board of Directors.
“His scientific and executive leadership have been pivotal in enabling the Company to successfully transition from a research and development company to a commercial organisation. We sincerely thank Dr. Melki for this and wish him the very best in his future endeavours.” said Dr. Nick Samaras, Chairman.
We thank John for his leadership, dedication to Genetic Signatures’ team and investors, and for his genuine passion for improving global health.
